FG-B901
/ FutureGen Biopharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 16, 2026
A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=120 | Not yet recruiting | Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd
New P1/2 trial • Oncology • Solid Tumor • CLDN18
June 04, 2026
A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=264 | Not yet recruiting | Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd
Monotherapy • New P1/2 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1